Over £435,000 awarded to new research exploring ways to manage Parkinson’s symptoms Date 2 Ebrill 2025
Parkinson’s UK commit further funding to develop drugs that protect mitochondria Date 4 Awst 2020 We’re investing a further £1 million to drive forward drugs that target energy-producing mitochondria to slow the loss of brain cells in Parkinson's.
Parkinson’s UK continues drug discovery with NRG Therapeutics Ltd. Date 3 Awst 2020 Parkinson's UK has invested an additional £1 million in NRG Therapeutics Ltd’s mitochondrial drug development programme.
How have coronavirus (COVID-19) restrictions impacted people affected by Parkinson’s? Date 2 July 2020 With Lancaster University, we conducted a survey that shows the coronavirus restrictions are having a big impact on the lives and the health of people affected by Parkinson’s.
Our response to Black Lives Matter Date 15 June 2020 Parkinson’s UK chose to stay quiet during the recent Black Lives Matter conversations. We believed that by giving others space to have their voices heard, we were playing a role in supporting their message. We were wrong.
Researchers identify key player in genetic Parkinson’s Date 29 Ebrill 2020 A team of researchers at the University of York have shown a protein called Rab10 plays an important role in the loss of brain cells in LRRK2-associated Parkinson’s.
Cannabis extract may hold key to stop pain in Parkinson's Date 5 Mawrth 2020 Cannabis-based compounds could be the silver bullet to relieve pain for people with Parkinson’s according to the largest ever study into pain and the condition.
Potential treatment for dyskinesia in Parkinson’s Date 2 Mawrth 2020 Results from a one-year project, funded through the Parkinson’s Virtual Biotech, suggest that NLX-112 has potential as a future treatment for reducing dyskinesia and improving movement symptoms of Parkinson’s.
Initial results from CDNF clinical trial announced Date 26 Chwefror 2020 Herantis Pharma has published initial results from a phase 1/2 study of an experimental protective protein called CDNF which may hold potential to slow, stop or reverse Parkinson's.
GDNF: where are we 1 year on? Date 25 Chwefror 2020 GDNF clinical trial results in 2019 revealed signs that GDNF may make it possible to repair the cells damaged in people with Parkinson’s. We take a look at where we are 1 year later.
Transparency and your Board of Trustees Date 19 Chwefror 2020 Over the next few months we plan to share who we are and what we’re doing for the charity. We hope you’ll get to know us better and we’ll know more about you.
